April 14th 2024
Patients with renal cell carcinoma who did not undergo surgical resection and were treated with stereotactic ablative body radiotherapy experienced high local control rates with an acceptable side effect profile.
January 29th 2024
December 14th 2023
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.